Tenax Therapeutics Inc. (TENX)
NASDAQ: TENX
· Real-Time Price · USD
6.03
0.15 (2.55%)
At close: Jun 06, 2025, 3:11 PM
2.55% (1D)
| Bid | 4.35 |
| Market Cap | 25.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.21M |
| EPS (ttm) | 1.69 |
| PE Ratio (ttm) | 3.57 |
| Forward PE | -2.45 |
| Analyst | Buy |
| Ask | 7.55 |
| Volume | 14,705 |
| Avg. Volume (20D) | 16,190 |
| Open | 5.90 |
| Previous Close | 5.88 |
| Day's Range | 5.82 - 6.06 |
| 52-Week Range | 2.77 - 7.89 |
| Beta | 1.62 |
About TENX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TENX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TENX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
+3.15%
Tenax Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
7 months ago
+10.65%
Tenax Therapeutics shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a price target of $16.
1 month ago · seekingalpha.com
Tenax: Phase 3 Heart Failure Program Continues With 2 Key CatalystsTenax Therapeutics is advancing levosimendan in two phase 3 studies for PH-HFpEF, with LEVEL-2 starting in 2025 and topline data from LEVEL expected mid-2026. Levosimendan could be the first disease-m...